Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma

Open access
Frigault, Matthew J., Dietrich, Jorg, Martinez-Lage, Maria, Leick, Mark, Choi, Bryan D., DeFilipp, Zachariah, Chen, Yi-Bin, Abramson, Jeremy, Crombie, Jennifer, Armand, Philippe, Nayak, Lakshmi, Panzini, Chris, Riley, Lauren S., Gallagher, Kathleen, Maus, Marcela V.·2019·Blood

Abstract

Chimeric antigen receptor (CAR) T cells targeting CD19 have emerged as a leading engineered T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The phase 1/2 clinical trials that led to US Food and Drug Administration approval excluded patients with central nervous system (CNS) involvement, due to strict eligibility criteria. Here, we report on our institutional experience with 8 secondary CNS lymphoma patients treated with commercial tisagenlecleucel. No patient experienced greater than grade 1 neurotoxicity, and no patient required tocilizumab or steroids for CAR T-cell–mediated toxicities. Biomarker analysis suggested CAR T-cell expansion, despite the absence of systemic disease, and early response assessments demonstrated activity of IV infused CAR T cells within the CNS space.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2019001694

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 242

Metadata

Authors
Frigault, M. J., Dietrich, J., Martinez-Lage, M., Leick, M., Choi, B. D., DeFilipp, Z., Chen, Y.-B., Abramson, J., Crombie, J., Armand, P., Nayak, L., Panzini, C., Riley, L. S., Gallagher, K., & Maus, M. V.
Venue
Blood
Published
2019-09-12
Volume
134
Issue
11
Pages
860-866
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2959588651
Cited by
242
References
5
FWCI
13.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. https://app.cochat.ai/papers/10.1182/blood.2019001694
The paper
Frigault, M. J., Dietrich, J., Martinez-Lage, M., Leick, M., Choi, B. D., DeFilipp, Z., Chen, Y.-B., Abramson, J., Crombie, J., Armand, P., Nayak, L., Panzini, C., Riley, L. S., Gallagher, K., & Maus, M. V. (2019). Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. https://doi.org/10.1182/blood.2019001694

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.